Lower dose of sufentanil was associated with higher plasmatic level of cortisol in patients undergoing elective cardiac surgery at the same depth of anaesthesia: a prospective randomised pilot study. Do we overlook ''stress under the surface''?

Objective monitoring of per-operative nociception remains an unanswered challenge. Anaesthetists still mostly rely on signs of activation of the sympathetic nervous system, e.g., an increase in heart rate and blood pressure. These signs can be often blurred in cardiac surgery because of medication influencing heart rate and blood pressure or by severe hemodynamic disturbances. Such conditions create the potential for incompletely checked nociception which can lead to unrecognised “under the surface” stress reaction. We decided to investigate whether patients undergoing cardiac surgery maintained at the same level of monitored depth of anaesthesia would express differences in plasmatic level of stress hormone cortisol when given a different dose of opioid sufentanil. Nineteen patients undergoing elective cardiac surgery were included in our prospective randomised trial. All patients were anaesthetised by a standardised protocol (using midazolam, propofol, sevoflurane, sufentanil and rocuronium) and were maintained within the same range of anaesthetic depth monitored by monitor Conox (qCON 30–50). Patients were randomised in two groups. Group LS (lower sufentanil), n = 9, recieved TCI (target controlled infusion) sufentanil in dose of 0.25 ng/mL, group HS (higher sufentanil), n = 10, in dose of 0.75 ng/mL. 15 minutes after sternotomy we took blood samples for analysis of plasmatic levels of cortisol. Group LS had significantly higher plasmatic cortisol levels, median 700 nm/L, than HS, median 328 nm/L (p = 0.006). We conclude that a lower dose of sufentanil was associated with higher plasmatic level of cortisol and thus more significant activation of hypothalamic–pituitary–adrenal axis stress response. We emphasise that activation of stress response can be underestimated during cardiac surgery. Our result supports the need for developing an objective monitoring method of per-operative nociception.

Cardiac anaesthesia; Analgesia; Nociception; Cortisol; Stress response

[1] Kelliher LJS, Scott M. Modifying the stress response—perioperative considerations and controversies. Anesthesiology Clinics. 2022; 40: 23–33.

[2] Cusack B, Buggy DJ. Anaesthesia, analgesia, and the surgical stress response. BJA Education. 2020; 20: 321–328.

[3] Funcke S, Pinnschmidt HO, Brinkmann C, Wesseler S, Beyer B, Fischer M, et al. Nociception level-guided opioid administration in radical retropubic prostatectomy: a randomised controlled trial. British Journal of Anaesthesia. 2021; 126: 516–524.

[4] Hyland SJ, Brockhaus KK, Vincent WR, Spence NZ, Lucki MM, Howkins MJ, et al. Perioperative pain management and opioid steward-ship: a practical guide. Healthcare. 2021; 9: 333.

[5] Lowenstein E, Hallowell P, Levine FH, Daggett WM, Austen WG, Laver MB. Cardiovascular response to large doses of intravenous morphine in man. The New England Journal of Medicine. 1969; 281: 1389–1393.

[6] Sebel PS, Bovill JG, Boekhorst RAA, Rog N. Cardiovascular effects of high-dose fentanyl anaesthesia. Acta Anaesthesiologica Scandinavica. 1982; 26: 308–315.

[7] Grant MC, Suffredini G, Cho BC. Is it time to eliminate the use of opioids in cardiac surgery? JTCVS Open. 2021; 7: 247–252.

[8] Goff J, Hina M, Malik N, McLardy H, Reilly F, Robertson M, et al. Can opioid-free anaesthesia be personalised? A narrative review. Journal of Personalized Medicine. 2023; 13: 500.

[9] Olausson A, Svensson CJ, Andréll P, Jildenstål P, Thörn S, Wolf A. Total opioid‐free general anaesthesia can improve postoperative outcomes after surgery, without evidence of adverse effects on patient safety and pain management: a systematic review and meta‐analysis. Acta Anaesthesiologica Scandinavica. 2022; 66: 170–185.

[10] Naguib AN, Tobias JD, Hall MW, Cismowski MJ, Miao Y, Barry N, et al. The role of different anesthetic techniques in altering the stress response during cardiac surgery in children. Pediatric Critical Care Medicine. 2013; 14: 481–490.

[11] Li X, Xiang H, Zhang W, Peng C. The effects of remifentanil combined with propofol on the oxidative damage and the stress and inflammatory responses in cardiac surgery patients. American Journal of Translational Research. 2021; 13: 4796–4803.

[12] Yin H, Cao L, Zhao H, Yang Y. Effects of dexmedetomide, propofol and remifentanil on perioperative inflammatory response and lung function during lung cancer surgery. American Journal of Translational Research. 2021; 13: 2537–2545.

[13] Abbott TEF, Pearse RM, Archbold RA, Ahmad T, Niebrzegowska E, Wragg A, et al. A rospective international multicentre cohort study of intraoperative heart rate and systolic blood pressure and myocardial injury after noncardiac surgery: results of the VISION study. Anesthesia and Analgesia. 2018; 126:1936–1945.

[14] Agerskov M, Thusholdt ANW, Holm-Sørensen H, Wiberg S, Meyhoff CS, Højlund J, et al. Erratum to ‘Association of the intraoperative peripheral perfusion index with postoperative morbidity and mortality in acute surgical patients: a retrospective observational multicentre cohort study’ (Br J Anaesth 2021; 127: 396–404). British Journal of Anaesthesia. 2022; 128: 744.

[15] Ochroch J, Usman A, Kiefer J, Pulton D, Shah R, Grosh T, et al. Reducing opioid use in patients undergoing cardiac surgery—preoperative, intraoperative, and critical care strategies. Journal of Cardiothoracic and Vascular Anesthesia. 2021; 35: 2155–2165.

[16] Urman RD, Seger DL, Fiskio JM, Neville BA, Harry EM, Weiner SG, et al. The burden of opioid-related adverse drug events on hospitalized previously opioid-free surgical patients. Journal of Patient Safety. 2021; 17: e76-e83.

[17] Krakowski JC, Hallman MJ, Smeltz AM. Persistent pain after cardiac surgery: prevention and management. Seminars in Cardiothoracic and Vascular Anesthesia. 2021; 25: 289–300.

[18] Rong LQ, Kamel MK, Rahouma M, Naik A, Mehta K, Abouarab AA, et al. High-dose versus low-dose opioid anesthesia in adult cardiac surgery: a meta-analysis. Journal of Clinical Anesthesia. 2019; 57: 57–62.

[19] Hirose M, Okutani H, Hashimoto K, Ueki R, Shimode N, Kariya N, et al. Intraoperative assessment of surgical stress response using nociception monitor under general anesthesia and postoperative complications: a narrative review. Journal of Clinical Medicine. 2022; 11: 6080.

[20] Ledowski T. Objective monitoring of nociception: a review of current commercial solutions. British Journal of Anaesthesia. 2019; 123: e312–e321.

[21] Martinez-Vazquez P, Jensen EW. Different perspectives for monitoring nociception during general anesthesia. Korean Journal of Anesthesiology. 2022; 75: 112–123.

[22] Bertolizio G, Garbin M, Ingelmo PM. Evaluation of nociception during pediatric surgery: a topical review. Journal of Personalized Medicine. 2023; 13: 260.

[23] Gruenewald M, Dempfle A. Analgesi/nociception monitoring for opioid guidance: meta-analysis of randomized clinical trials. Minerva Anestesi-ologica. 2017; 83: 200–213.

[24] Jiao Y, He B, Tong X, Xia R, Zhang C, Shi X. Intraoperative monitoring of nociception for opioid administration: a meta-analysis of randomized controlled trials. Minerva Anestesiologica. 2019; 85: 522–530.

[25] Gepts E, Shafer SL, Camu F, Stanski DR, Woestenborghs R, Van Peer A, et al. Linearity of pharmacokinetics and model estimation of sufentanil. Anesthesiology. 1995; 83: 1194–1204.

[26] Mohd Azmi NAS, Juliana N, Azmani S, Mohd Effendy N, Abu IF, Mohd Fahmi Teng NI, et al. Cortisol on circadian rhythm and its effect on cardiovascular system. International Journal of Environmental Research and Public Health. 2021; 18: 676.

[27] Khoo B, Boshier PR, Freethy A, Tharakan G, Saeed S, Hill N, et al. Redefining the stress cortisol response to surgery. Clinical Endocrinology. 2017; 87: 451–458.

[28] Manou-Stathopoulou V, Korbonits M, Ackland GL. Redefining the perioperative stress response: a narrative review. British Journal of Anaesthesia. 2019; 123: 570–583.

[29] Yamaji M, Tsutamoto T, Kawahara C, Nishiyama K, Yamamoto T, Fujii M, et al. Serum cortisol as a useful predictor of cardiac events in patients with chronic heart failure. Circulation. Heart Failure. 2009; 2: 608–615.

[30] Duncan HP, Cloote A, Weir PM, Jenkins I, Murphy PJ, Pawade AK, et al. Reducing stress responses in the pre-bypass phase of open heart surgery in infants and young children: a comparison of different fentanyl doses. British Journal of Anaesthesia. 2000; 84: 556–564.

[31] Weale NK, Rogers CA, Cooper R, Nolan J, Wolf AR. Effect of remifentanil infusion rate on stress response to the pre-bypass phase of paediatric cardiac surgery. British Journal of Anaesthesia. 2004; 92: 187–194.

[32] Naguib AN, Tobias JD, Hall MW, Cismowski MJ, Miao Y, Barry N, et al. The role of different anesthetic techniques in altering the stress response during cardiac surgery in children. Pediatric Critical Care Medicine. 2013; 14: 481–490.

[33] Jensen EW, Valencia JF, López A, Anglada T, Agustí M, Ramos Y, et al. Monitoring hypnotic effect and nociception with two EEG-derived indices, qCON and qNOX, during general anaesthesia. Acta Anaesthesiologica Scandinavica. 2014; 58: 933–941.

[34] Müller JN, Kreuzer M, García PS, Schneider G, Hautmann H. Monitoring depth of sedation: evaluating the agreement between the bispectral index, qCON and the entropy module’s state entropy during flexible bronchoscopy. Minerva Anestesiologica. 2017; 83: 563–573.

[35] Christenson C, Martinez-Vazquez P, Breidenstein M, Farhang B, Mathews J, Melia U, et al. Comparison of the Conox (qCON) and Sedline (PSI) depth of anaesthesia indices to predict the hypnotic effect during desflurane general anaesthesia with ketamine. Journal of Clinical Monitoring and Computing. 2021; 35: 1421–1428.

[36] Pantalacci T, Allaouchiche B, Boselli E. Relationship between ANI and qNOX and between MAC and qCON during outpatient laparoscopic cholecystectomy using remifentanil and desflurane without muscle relaxants: a prospective observational preliminary study. Journal of Clinical Monitoring and Computing. 2023; 37: 83–91.

[37] Vail EA, Shieh M, Pekow PS, Gershengorn HB, Walkey AJ, Lindenauer PK, et al. Use of vasoactive medications after cardiac surgery in the United States. Annals of the American Thoracic Society. 2021; 18: 103–111.

[38] Shankar A, Gurumurthy G, Sridharan L, Gupta D, Nicholson WJ, Jaber WA, et al. A clinical update on vasoactive medication in the management of cardiogenic shock. Clinical Medicine Insights. 2022; 16: 117954682210750.

[39] Guarracino F, Habicher M, Treskatsch S, Sander M, Szekely A, Paternoster G, et al. Vasopressor therapy in cardiac surgery—an experts’ consensus statement. Journal of Cardiothoracic and Vascular Anesthesia. 2021; 35: 1018–1029.